Evaluation of different tests based on observations for external model evaluation of population analyses. Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method. Mesnil F, Mentré F, Dubruc C, Thénot JP, Mallet A. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. 2006 33:345–67.īrendel K, Comets E, Laffont C, Laveille C, Mentré F. Prediction discrepancies for the evaluation of nonlinear mixed-effects models. Guidance for industry exposure-response relationships– study design, data analysis, and regulatory applications 2019. Guideline on reporting the results of population pharmacokinetic analysis (CHMP) 2007. Some suggestions for measuring predictive performance. Modelling of individual pharmacokinetics for computer- aided drug dosage. Optimal design in random-effects regression models. nlmixr: nonlinear mixed effects models in population pharmacokinetics and pharmacodynamics 2021. 2017 80:1–41.įidler M, Xiong Y, Schoemaker R, Wilkins J, Trame M, Hooijmaijers R, et al. Parameter estimation in nonlinear mixed effect models using saemix, an R implementation of the SAEM algorithm. Fitting linear mixed-effects models using lme4. nlme: linear and nonlinear mixed effects models 2020. Pinheiro J, Bates D, DebRoy S, Sarkar D, R Core Team. Stan: a probabilistic programming language.
NPDE NONMEM SERIES
Chapman & Hall/CRC Biostatistics Series 2014.Ĭarpenter B, Gelman A, Hoffman M, Lee D, Goodrich B, Betancourt M, et al. Mixed effects models for the population approach: models, tasks, methods and tools. 2014 3:e154.īeal S, Sheiner L, Boeckmann A, Bauer R. Lewis Sheiner ISoP/UCSF lecturer award: from drug use to statistical models and vice versa. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.